When a Wegovy savings card is off the table, five routes remain: the manufacturer’s own cash-pay channel, a formulary exception or appeal, a switch to a different covered anti-obesity drug, a nonprofit assistance grant, or supervised compounded semaglutide. Each has a different qualifying test, and only some of them involve insurance at all.
Why the card stops working for so many people
Manufacturer copay cards are built for one situation: a patient with commercial insurance whose plan already covers the drug, where the card absorbs part of the copay that remains. Three groups fall outside that design.
People whose drug benefit runs through Medicare, Medicaid, TRICARE, or the VA are excluded from commercial copay assistance. People whose commercial plan excludes anti-obesity medication as a benefit category have no copay for a card to reduce. And people with no coverage at all were never the intended user in the first place.
That last group is larger than the marketing suggests. Employer plans frequently carve weight management drugs out entirely, and Medicare Part D has historically been barred from paying for products prescribed solely for weight loss, which is why coverage discussions for older adults usually turn on whether a separate qualifying indication exists.
Route 1: the manufacturer’s direct cash channel
Novo Nordisk sells Wegovy to cash-paying patients through its own pharmacy channel, and Eli Lilly runs an equivalent channel for Zepbound. Both are built the same way: a set price per month paid without insurance, usually conditioned on staying on schedule with refills, sometimes varying by dose or by whether the first month carries an introductory rate.
This is the first thing to price, because it is the only route that produces an FDA-approved product at a cash figure rather than a list figure. Read the conditions closely. The published number generally assumes uninterrupted refills, and missing a window can move a patient to a different rate.
Before settling on the manufacturer figure, it is worth seeing what the wider telehealth field charges for the same molecule, since those numbers move independently of Novo Nordisk. Providers such as Ro, Hims and Hers, Henry Meds, and HealthRX each post their own monthly pricing, and a reference page like the HealthRX breakdown of Wegovy cost shows roughly where the direct-pay routes land. None of them is the drugmaker, so pricing two or three before committing is the only reliable way to tell which is cheaper for a given dose.
Route 2: appeal the plan instead of accepting the denial
A denial is not always an exclusion. Often it is a prior authorization that was never finished. Authorization for anti-obesity medication typically asks for a documented body mass index, frequently a weight-related condition such as hypertension, sleep apnea, or dyslipidemia, and sometimes evidence that a supervised lifestyle intervention was tried first.
Where the plan does cover the category, completing that paperwork properly resolves a meaningful share of denials. Where the plan excludes the category outright, an exception request is still possible but much less likely to land, and the faster move is to price the cash routes. Establishing which of the two you are facing, missing documentation or an excluded benefit, is the most useful thing to do in the first week.
Route 3: a different medication the plan already covers
Semaglutide is not the only agent with evidence behind it. Liraglutide, tirzepatide, phentermine-topiramate, and naltrexone-bupropion all appear in current obesity pharmacotherapy guidance, and a plan that excludes one sometimes covers another. Updated 2025 clinical guidance frames agent selection around comorbidity, tolerability, and access rather than a fixed ranking.
The trade-off is real. Trial data established a large average effect for semaglutide in the STEP program, and tirzepatide produced larger average reductions in its own separate trials. Those were different studies in different populations, so the numbers are not a head-to-head result. Even so, a covered older agent taken for two years frequently produces a better outcome than a stronger drug abandoned after two months.
Route 4: foundation and nonprofit assistance
Independent charitable foundations sometimes fund out-of-pocket drug costs for people caught between coverage and affordability, including Medicare beneficiaries who are locked out of manufacturer cards. Funds open and close depending on donations, eligibility usually keys off household income relative to the federal poverty level, and weight management is funded far less often than oncology or rare disease.
It is worth one phone call rather than a long wait. Treat it as a supplement to the other routes rather than a replacement for them.
Route 5: supervised compounded semaglutide
Compounded semaglutide is prepared by a compounding pharmacy rather than manufactured under an approved application. It is not an FDA-approved product, and the trial evidence behind the brand does not transfer to it. Pharmacovigilance reporting has documented dosing errors with compounded preparations serious enough to reach poison control centers, most often when a patient measures a dose from a multi-dose vial.
What the route offers is a predictable monthly cash figure with no insurance adjudication in the way. Telehealth practices that work this way, including FormBlends, publish a flat monthly price and route prescribing through a licensed clinician instead of selling the product directly. For someone whose plan excludes the category and who cannot absorb the brand cash price, that predictability is frequently what decides it.
How the routes compare
| Route | Insurance needed | What sets the price | Main catch |
|---|---|---|---|
| Manufacturer cash channel | No | Price set by the manufacturer | Refill timing conditions, dose-dependent rates |
| Appeal or formulary exception | Yes | Tier and coinsurance after approval | Fails when the category is excluded |
| Different covered drug | Yes | Existing copay structure | Different efficacy and tolerability profile |
| Foundation grant | Varies | Grant size and fund availability | Income tested, funds close without notice |
| Compounded semaglutide | No | Pharmacy and provider pricing | Not an FDA-approved product |
What is usually not worth chasing
Third-party pharmacy discount cards negotiate a cash price against a pharmacy’s usual charge. On generic tablets that works well. On a high-list-price branded injectable it rarely gets close to what a manufacturer’s own cash channel produces, so it is a poor first stop for this particular drug.
Importing from outside the country is the other dead end. It carries no assurance about what is in the vial, no recourse if something is wrong, and no prescriber attached to the outcome.
Frequently asked questions
Can someone on Medicare use a Wegovy savings card?
No. Commercial copay assistance excludes beneficiaries of federal health programs, including Medicare, Medicaid, TRICARE, and VA coverage, and that exclusion applies regardless of income. Medicare beneficiaries who need help generally have to look at nonprofit foundation grants or a cash-pay route instead.
Is the manufacturer cash price the same thing as the coupon price?
No, they are separate programs. A savings card reduces a copay that already exists under commercial coverage. The direct cash channel replaces insurance entirely with a set monthly figure. Someone without coverage is aiming at the second one, and the two numbers are not interchangeable.
Does compounded semaglutide work the same way as the brand?
It contains the same active molecule, but it is not an FDA-approved product and has not been through the approval process that generated the published trial data. Concentration, excipients, and labeling vary between pharmacies, which is why prescriber supervision carries more weight on this route.
How long should an appeal run before switching routes?
Plans face deadlines for standard authorization decisions, and expedited review is faster still. If the denial language reads as a benefit exclusion rather than as missing documentation, pricing the cash routes at the same time avoids losing a month waiting for an answer that was never going to change.
Do the alternatives change if treatment is already underway?
Continuity matters more than the starting price. Trial extension data shows weight returns after semaglutide is stopped, so a route that can be sustained for years is worth more than a cheaper one that ends when a program year rolls over or a fund closes.
